UBS Group’s AdaptHealth AHCO Stock Holding History

UBS Group’s Portfolio AHCO Stock Details AHCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,600	Closed	-$574K	–	10423
2025 Q4	$574K	Buy	+57,600	New	+$550K	﹤0.01%	5997

Other funds holding AHCO

OCA

OEP Capital Advisors New York $170M AUM 10.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SkyKnight Capital San Francisco, California $94.1M AUM 10.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Reinhart Partners Mequon, Wisconsin $4.38B AUM 55.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's AHCO Position: Q2 2026 in Review

UBS Group reduced its AdaptHealth (AHCO) stake by 47% in Q2 2026, selling an estimated $2.93M and leaving 297,038 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #4663.

UBS Group first reported a position in AHCO in Q4 2018 and has held it in 30 quarters since. The position peaked at $22.8M in Q2 2021. 239 funds tracked by Wall St. Rank hold AHCO as of Q2 2026.

UBS Group held 297,038 shares of AdaptHealth worth $3.1M as of Q2 2026.
UBS Group sold 262,377 AdaptHealth shares in Q2 2026, an estimated $2.93M.
AdaptHealth made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4663 holding.
UBS Group first reported a position in AdaptHealth in Q4 2018 and has held it in 30 quarters since.
UBS Group's AdaptHealth position peaked at $22.8M in Q2 2021.
239 funds tracked by Wall St. Rank held AdaptHealth as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.